The Phase IIb trial of mesdopetam (partnered with Ipsen) in levodopa-induced dyskinesias in Parkinso...
Kiliaro fortsatte med att växa användarbasen kraftigt i andra kvartalet för 2022, vilket fortsatt är...
Redeye comments on Fluoguide’s Q2 2022 report, and we judge that the company is laser-focused on del...
Redeye is encouraged by the strong Q1 report, which is a new record-level in terms of both sales and...
Today (25 August), Cibus’ CEO Sverker Källgården and CFO Pia-Lena Olofsson presented at the Nordea S...
Intellego Technologies publicerade den 25 augusti år 2022 bolagets delårsrapport för andra kvartalet...
Redeye comments on Cereno’s Q2 2022 report, and we judge that the company is making solid progress o...
AcouSort publicerade den 24:e augusti 2022 sin delårsrapport för Q2-22.
E-tailers stack ut i kvartalet Björn Borg hade en omsättning om 162 mkr (163 mkr) i Q2, motsvarande ...
Redeye comments briefly on the rights issue outcome of SEK 215m raised and adjusts our fair value ra...
Redeye comments on today’s Q2 report from Alzecure and reiterate our view of the company.
Redeye comments on BioInvent's second quarter report.
Fellow Bank started its banking operations in April and financial figures were accordingly burdened.
Redeye comments on Scandion’s Q2 2022 report, coming shortly before the company plans to communicate...
Med första halvåret avklarat står det klart att Finepart fortsätter att uppvisa ett starkt momentum,...
Zoomability publicerade den 24 augusti 2022 bolagets delårsrapport för årets andra kvartal.
Redeye will only make smaller estimate changes as the quarterly financials were somewhat weaker than...
Redeye states that the Q2 report was weaker than expected but that mobile accessories delivered good...
Redeye leaves a comment on the H1 report published by Faron Pharmaceuticals earlier today.
Redeye will likely only make smaller estimate changes after Gapwaves’ Q2 2022 report, wherein it pos...
